| Metric | Value ($ M) | vs Q2 FY25 |
|---|---|---|
| Revenue | 12.50 | 150.0% |
| Total Income | 12.50 | 150.0% |
| Expenditure | 31.39 | 43.6% |
| PBT | -16.70 | 15.9% |
| Net Profit | -16.70 | 12.0% |
| OPM | — | |
| NPM | — | |
| EPS | -0.59 | 11.3% |
LENZ Therapeutics Reports Q3 2025 Financial Results
04 May 2026 · 4 May, 8:05 am
Summary
LENZ Therapeutics reported its financial results for the third quarter ended September 30, 2025. The company announced FDA approval and commercial launch of VIZZ for the treatment of presbyopia. Over 2,500 ECPs prescribed VIZZ, resulting in over 5,000 prescriptions filled through October 2025. The company partnered with Sarah Jessica Parker for a direct-to-consumer campaign. Cash, cash equivalents, and marketable securities were $202.2 million as of September 30, 2025, with a pro forma balance of approximately $324.0 million.
Key Highlights
- 1
LENZ Therapeutics' VIZZ received FDA approval for the treatment of presbyopia.
- 2
The commercial product launch of VIZZ commenced in October 2025, with broad availability expected in mid-Q4 2025.
- 3
Over 2,500 Eye Care Professionals (ECPs) prescribed VIZZ, with 40% prescribing multiple times, resulting in over 5,000 prescriptions filled through October 2025.
- 4
LENZ Therapeutics partnered with Sarah Jessica Parker as the direct-to-consumer campaign spokesperson, with the campaign anticipated to launch in Q1 2026.
- 5
The company achieved and received $10 million in milestone payments under its agreement with CORXEL Pharmaceuticals in China.
- 6
Cash, cash equivalents, and marketable securities totaled $202.2 million as of September 30, 2025, and pro forma cash was approximately $324.0 million after utilizing the remaining capacity under its sales agreement in October 2025.
- 7
License revenue was $12.5 million for the three months ended September 30, 2025 and $17.5 million for the nine months ended September 30, 2025.
Management Comments
Eef Schimmelpennink
“We are very pleased with the first weeks of the VIZZ launch as we introduce our exciting new solution for the treatment of presbyopia into the marketplace and have been highly encouraged by the enthusiasm from the ECP community, as evidenced by the over 2,500 unique prescribers and impressively over 5,000 prescriptions filled through October. Early patient feedback has been very positive, and it is undisputed that VIZZ is highly effective at restoring near vision with rapid onset and long duration. “The months ahead promise to continue to be very exciting, and we are proud to announce today our partnership with Sarah Jessica Parker as campaign spokesperson to lead the VIZZ DTC campaign which we intend to launch in Q1 2026.”
Informational and educational content only. Not investment advice.